Eton Pharmaceuticals, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 32/100
What the filing says
Eton Pharmaceuticals amended its credit agreement with SWK Funding LLC on April 9, 2026. The Term Loan Commitment increased from $30M to $40M, with a new optional $10M tranche (Subsequent Term Loan C) available through November 2026. Term Loan Maturity Date extended to December 17, 2027. Interest rate (Contract Rate) reduced from 6.75% to 6.55% above Term SOFR. SWK remains sole lender with 100% pro rata share. Amendment contingent on Runway Growth Finance Corp merger completion.
Why this rating
Standard credit facility amendment expanding borrowing capacity and extending maturity. $10M incremental option modest relative to $360.6M market cap. Rate reduction ~0.2% favorable. No material covenant changes disclosed. Routine refinancing activity.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.